Experienced life sciences development team and distinguished scientists with a track record of success
Our Commitment to Data-driven Science
First to discover
A novel, narrow-spectrum drug that kills Borrelia burgdorferi with limited impact on healthy gut microbiome
A single, targeted-formulation of an approved drug that kills co-infectious bacteria in Lyme disease and limits microbiome damage
A distinct microbiome signature with potential to become the first diagnostic for patients with chronic Lyme disease
A therapeutic candidate with potential to treat multiple pathogenic bacteria in both the oral and gut microbiome
Leadership
Mark de Souza, PhD
Co-Founder and Executive Chairman
Matthew Tindall, MBA
Co-Founder, President and Chief Executive Officer
Mark de Souza, PhD
Co-Founder and Executive Chairman
Matthew Tindall, MBA
Co-Founder, President and Chief Executive Officer
Curtis Scribner, MD, MBA
Co-Founder, Chief Medical Officer and Head of Clinical and Regulatory
James Kanter
VP, Operations and Manufacturing
Kip Vought
Regulatory Strategy
Monil Shah, PharmD, MBA
Clinical Development Strategy
Kim Lewis
Dr Charles Chiu
Monica E. Embers